HOWL
NASDAQWerewolf Therapeutics Inc.
Werewolf Therapeutics Inc. (HOWL) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for HOWL, including 2 SEC filings and 2 press releases and news items. The most recent was published Nov 9, 2026.
HOWL rankings
Financial highlights
Full financials- Net income, TTM
- -$34.61M
- Cash
- $21.99M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks53+100%
2026-05-172026-11-08
Mix1190d
- SEC Filings6(55%)
- Other3(27%)
- Offering2(18%)
Activity · 52 weeks17162 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECWerewolf Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
- PRWerewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual MeetingIn a Phase 1/1b clinical trial, WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the outpatient setting as monotherapy and in combination with pembrolizumab, with durable antitumor activity in patients with relapsed/refractory immunotherapy-sensitive solid tumors -Aligned with FDA on a recommended Phase 2 dose of 18 mg IV Q2W for WTX-124 as monotherapy and in combination with pembrolizumab -In a Phase 1b/2 clinical trial, WTX-330 was well tolerated using an optimized drug product and demonstrated monotherapy antitumor activity in patients with advanced, treatment refractory solid tumors - WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeu
- PRWerewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual MeetingWALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it has been selected for an oral presentation and will present two posters at the upcoming Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona. Oral Presentation Details Title: A Phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with re
- SECAmendment: SEC Form S-4/A filed by Werewolf Therapeutics Inc.S-4/A - Werewolf Therapeutics, Inc. (0001785530) (Filer)
- SECSEC Form S-4 filed by Werewolf Therapeutics Inc.S-4 - Werewolf Therapeutics, Inc. (0001785530) (Filer)
- SECSEC Form SCHEDULE 13G filed by Werewolf Therapeutics Inc.SCHEDULE 13G - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 425 filed by Werewolf Therapeutics Inc.425 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECWerewolf Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
- PRWerewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private PlacementProposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. patients annually and no currently FDA-approved therapyPivotal CRPS-RISE Phase 3 trial evaluating neridronate remains ongoing, with FDA Breakthrough Therapy, Fast Track and Orphan Drug designations received and alignment with FDA that a single successful pivotal trial could potentially support approvalNeridronate has been administered to approximately 600,000 patients in Italy across approved indications including CRPS-1Concurrent oversubscribed private placement of $150 million f
- PRWerewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private PlacementProposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. patients annually and no currently FDA-approved therapyPivotal CRPS-RISE Phase 3 trial evaluating neridronate remains ongoing, with FDA Breakthrough Therapy, Fast Track and Orphan Drug designations received and alignment with FDA that a single successful pivotal trial could potentially support approvalNeridronate has been administered to approximately 600,000 patients in Italy across approved indications including CRPS-1Concurrent oversubscribed private placement of $150 million f
- SECSEC Form 8-K filed by Werewolf Therapeutics Inc.8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
- SECSEC Form 10-Q filed by Werewolf Therapeutics Inc.10-Q - Werewolf Therapeutics, Inc. (0001785530) (Filer)
- SECWerewolf Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
- PRWerewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate UpdatesWATERTOWN, Mass., July 31, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported financial results for the second quarter ended June 30, 2026. "In the second quarter of 2026, as previously announced, Werewolf entered into an asset purchase agreement with Jazz Pharmaceuticals Ireland Limited ("Jazz") with respect to the JZP898 program previously licensed to Jazz, and repaid all amoun
- INSIDERDirector Evnin Luke sold $44,749 worth of shares (143,199 units at $0.31) as part of a pre-agreed trading plan (SEC Form 4)4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Werewolf Therapeutics Inc.SCHEDULE 13D/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- INSIDERDirector Evnin Luke sold $47,125 worth of shares (157,084 units at $0.30) as part of a pre-agreed trading plan (SEC Form 4)4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
HOWL FAQ
10 questionsWhat does Werewolf Therapeutics Inc. do?
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or...What is the latest news on HOWL?
In the last 30 days Quantisnow tracked 4 wire items for HOWL: 2 SEC filings and 2 press releases and news items. The most recent was published on November 9, 2026.Is HOWL profitable?
No. Werewolf Therapeutics Inc. reported a net loss of $34.61M for the twelve months ended Jun 30, 2026.How much cash and debt does HOWL have?
Werewolf Therapeutics Inc. reported $21.99M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does HOWL stock trade?
Werewolf Therapeutics Inc. (HOWL) is listed on NASDAQ.What sector and industry is HOWL in?
Werewolf Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Werewolf Therapeutics Inc. go public?
Werewolf Therapeutics Inc. (HOWL) completed its IPO in 2021.What are analysts saying about HOWL?
Across the last 6 analyst actions on Werewolf Therapeutics Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Wedbush: Neutral with a $1.00 price target on 2025-12-19.What companies are similar to HOWL?
Notable peers in the same industry include MRK (Merck & Company Inc.), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare HOWL side-by-side with any of them on Quantisnow.How can I track HOWL on Quantisnow?
Quantisnow aggregates Werewolf Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HOWL to receive live email and push alerts on every new disclosure.